New HDAC1 Inhibitor Crosses Blood-Brain Barrier to Fight Glioblastoma via Mitophagy
Iodo-phenanthroimidazole compound 3 kills glioblastoma cells at nanomolar doses and penetrates the blood-brain barrier in zebrafish models.
Summary
Glioblastoma is the most aggressive primary brain tumor, with few effective treatments and high recurrence rates. Researchers at Guangdong Pharmaceutical University designed a new class of molecules — iodo-phenanthroimidazole derivatives — that inhibit HDAC1, an enzyme involved in gene regulation and cancer progression. The lead compound (compound 3) bound tightly to HDAC1's active site, halted glioblastoma cell growth at an impressively low dose (IC50 of 0.23 micromolar), and triggered mitophagy — a cellular process that selectively destroys damaged mitochondria. Importantly, the compound crossed the blood-brain barrier and suppressed tumor growth and spread in living zebrafish models. These findings suggest that targeting HDAC1 while simultaneously inducing mitophagy could be a powerful new strategy for treating one of the deadliest brain cancers.
Detailed Summary
Glioblastoma multiforme (GBM) remains one of the most lethal human cancers, with median survival under 15 months despite surgery, radiation, and chemotherapy. High recurrence and resistance to existing therapies make novel targeted agents urgently needed — particularly those capable of crossing the blood-brain barrier (BBB). This study addresses that gap by introducing a new chemical scaffold with potent anti-GBM activity.
Researchers used a combined computational and experimental approach to develop iodo-phenanthroimidazole derivatives targeting HDAC1, a histone deacetylase enzyme frequently overexpressed in glioblastoma and linked to tumor survival and proliferation. Molecular docking and dynamics simulations identified compound 3 as the lead candidate, showing stable binding to the HDAC1 catalytic site with estimated binding energies near -7.75 kcal/mol and a key halogen bond involving the iodine atom and Asp104.
Biophysical validation confirmed strong binding affinity (Kd = 1.04 × 10⁻⁷ M) via isothermal titration calorimetry. In vitro testing against U87-MG glioblastoma cells showed potent antiproliferative activity (IC50 = 0.23 µM) with concurrent cell cycle arrest at both G2/M and S phases. Electron microscopy and immunofluorescence revealed hallmarks of mitophagy — selective autophagy of damaged mitochondria — including autophagic vacuoles, elevated LC3-II/LC3-I ratios, mitochondrial membrane potential loss, and ATP depletion.
In a zebrafish orthotopic GBM model, compound 3 demonstrated BBB penetration, suppressed primary tumor growth, and reduced metastatic spread of U87-MG cells — a critical translational milestone for brain cancer drug development.
These results position HDAC1 inhibition coupled with mitophagy induction as a promising dual-mechanism strategy for GBM. Caveats include the preclinical-only nature of the work, reliance on a single cell line, and abstract-only availability of full data. Mammalian in vivo efficacy and toxicity studies are essential next steps before clinical translation.
Key Findings
- Compound 3 inhibited glioblastoma cell proliferation with an IC50 of 0.23 µM, indicating high potency.
- HDAC1 binding was confirmed biophysically with submicromolar affinity (Kd = 1.04 × 10⁻⁷ M).
- The compound induced mitophagy — selective destruction of damaged mitochondria — in cancer cells.
- Compound 3 crossed the blood-brain barrier and suppressed tumor growth in a zebrafish GBM model.
- Cell cycle arrest occurred at both G2/M and S phases, suggesting multi-point disruption of cancer proliferation.
Methodology
The study combined molecular docking, molecular dynamics simulation, and isothermal titration calorimetry for target validation, then assessed antiproliferative activity, cell cycle effects, and mitophagy markers in U87-MG glioblastoma cells in vitro. In vivo efficacy and BBB penetration were evaluated using a zebrafish orthotopic glioblastoma model.
Study Limitations
This summary is based on the abstract only, as the full paper is not open access, limiting assessment of complete data and statistical rigor. All efficacy data are preclinical — in vitro (single cell line) and zebrafish — with no mammalian in vivo or toxicology data reported. The mechanistic link between HDAC1 inhibition and mitophagy induction requires further mechanistic dissection in more complex models.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: